FONTANA, DILETTA
FONTANA, DILETTA
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer
2025 Zapata Dongo, R; Fontana, D; Mologni, L; Faya Castillo, J; Infante Varillas, S
Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer
2025 Zapata Dongo, R; Fontana, D; Mologni, L; Faya Castillo, J; Infante, V
Abstract 987: Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy
2024 Malighetti, F; Villa, M; Sala, E; Geeta, G; Arosio, G; Gemelli, M; Manfroni, C; Fontana, D; Cordani, N; Meneveri, R; Zambon, A; Piazza, R; Pagni, F; Cortinovis, D; Mologni, L
Behavior of the anti-apoptotic BCL-2 protein in non-small-cell lung cancer cell models in response to treatments with ALK inhibitors and its potential dual BCL2-ALK inhibition
2024 Zapata-Dongo, R; Fontana, D; Mologni, L; Faya-Castillo, J; Silva-Torres, F; Moy-Diaz, B; Infante-Varillas, S
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis
2024 Crespiatico, I; Zaghi, M; Mastini, C; D'Aliberti, D; Mauri, M; Mercado, C; Fontana, D; Spinelli, S; Crippa, V; Inzoli, E; Manghisi, B; Civettini, I; Ramazzotti, D; Sangiorgio, V; Gengotti, M; Brambilla, V; Aroldi, A; Banfi, F; Barone, C; Orsenigo, R; Riera, L; Riminucci, M; Corsi, A; Breccia, M; Morotti, A; Cilloni, D; Roccaro, A; Sacco, A; Stagno, F; Serafini, M; Mottadelli, F; Cazzaniga, G; Pagni, F; Chiarle, R; Azzoni, E; Sessa, A; Gambacorti Passerini, C; Elli, E; Mologni, L; Piazza, R
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis Mimicking Triple Negative Myelofibrosis
2024 Fontana, D; Crespiatico, I; Zaghi, M; Mastini, C; D’Aliberti, D; Mauri, M; Mercado, C; Spinelli, S; Crippa, V; Inzoli, E; Manghisi, B; Civettini, I; Ramazzotti, D; Sangiorgio, V; Gengotti, M; Brambilla, V; Aroldi, A; Banfi, F; Barone, C; Orsenigo, R; Riera, L; Riminucci, M; Corsi, A; Breccia, M; Morotti, A; Cilloni, D; Roccaro, A; Sacco, A; Stagno, F; Serafini, M; Mottadelli, F; Cazzaniga, G; Pagni, F; Chiarle, R; Azzoni, E; Sessa, A; Gambacorti-Passerini, C; Elli, E; Mologni, L; Piazza, R
Idiopathic erythrocytosis: a germline disease?
2024 Elli, E; Mauri, M; D’Aliberti, D; Crespiatico, I; Fontana, D; Redaelli, S; Pelucchi, S; Spinelli, S; Manghisi, B; Cavalca, F; Aroldi, A; Ripamonti, A; Ferrari, S; Palamini, S; Mottadelli, F; Massimino, L; Ramazzotti, D; Cazzaniga, G; Piperno, A; Gambacorti-Passerini, C; Piazza, R
Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer
2024 Crippa, V; Fontana, D; Civettini, I; Mologni, L; Piazza, R; Gambacorti Passerini, C; Ramazzotti, D
Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape
2024 Fontana, D; Zambrotta, G; Scannella, A; Piazza, R; Gambacorti-Passerini, C
miR-15a targets the HSP90 co-chaperone Morgana in chronic myeloid leukemia
2024 Poggio, P; Rocca, S; Fusella, F; Ferretti, R; Ala, U; D'Anna, F; Giugliano, E; Panuzzo, C; Fontana, D; Palumbo, V; Carrà, G; Taverna, D; Gambacorti-Passerini, C; Saglio, G; Fava, C; Piazza, R; Morotti, A; Orso, F; Brancaccio, M
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients
2024 Villa, M; Malighetti, F; Sala, E; Sharma, G; Arosio, G; Gemelli, M; Manfroni, C; Fontana, D; Cordani, N; Meneveri, R; Zambon, A; Piazza, R; Pagni, F; Cortinovis, D; Mologni, L
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma
2024 Villa, M; Geeta, G; Malighetti, F; Mauri, M; Arosio, G; Cordani, N; Lobello, C; Larose, H; Pirola, A; D'Aliberti, D; Massimino, L; Criscuolo, L; Pagani, L; Chinello, C; Mastini, C; Fontana, D; Bombelli, S; Meneveri, R; Lovisa, F; Mussolin, L; Janikova, A; Pospíšilová, Š; Turner, S; Inghirami, G; Magni, F; Urso, M; Pagni, F; Ramazzotti, D; Piazza, R; Chiarle, R; Gambacorti-Passerini, C; Mologni, L
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1
2024 Fontana, D; Malighetti, F; Villa, M; Zambon, A; Gambacorti-Passerini, C; Mologni, L
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1
2024 Fontana, D; Malighetti, F; Villa, M; Zambon, A; Gambacorti-Passerini, C; Mologni, L
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients
2023 Fontana, D; Crespiatico, I; Crippa, V; Malighetti, F; Villa, M; Angaroni, F; De Sano, L; Aroldi, A; Antoniotti, M; Caravagna, G; Piazza, R; Graudenzi, A; Mologni, L; Ramazzotti, D
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis
2023 Crespiatico, I; Zaghi, M; Mastini, C; D'Aliberti, D; Mauri, M; Mercado, C; Fontana, D; Spinelli, S; Crippa, V; Inzoli, E; Manghisi, B; Civettini, I; Ramazzotti, D; Lavoro, V; Gengotti, M; Brambilla, V; Aroldi, A; Banfi, F; Barone, C; Orsenigo, R; Riera, L; Riminucci, M; Corsi, A; Breccia, M; Morotti, A; Cilloni, D; Roccaro, A; Sacco, A; Stagno, F; Serafini, M; Mottadelli, F; Cazzaniga, G; Pagni, F; Chiarle, R; Azzoni, E; Sessa, A; Gambacorti-Passerini, C; Elli, E; Mologni, L; Piazza, R
Integrating mutational profiles and single-cell transcriptional data using LASSO regularized regression to elucidate key molecular functions involved in the pathogenesis of myelodysplastic/myeloproliferative neoplasm (MDS/MPN) with neutrophilia
2023 Crippa, V; Fontana, D; Bassi, G; D’Aliberti, D; Mauri, M; Spinelli, S; Mastini, C; Bombelli, S; Civettini, I; Guglielmana, V; Ripamonti, A; Perego, R; Mologni, L; Piazza, R; Gambacorti-Passerini, C; Ramazzotti, D
Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review
2023 Fontana, D; Elli, E; Pagni, F; Piazza, R
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia
2022 Gambacorti-Passerini, C; Nicolini, F; Larson, R; Aroldi, A; Fontana, D; Piazza, R; le Coutre, P; Antolini, L; Assouline, S
Characterization of the transcriptional landscape of atypical Chronic Myeloid Leukemia at single-cell resolution
2022 Fontana, D; Crippa, V; Bassi, G; D'Aliberti, D; Mauri, M; Spinelli, S; Mastini, C; Bombelli, S; Civettini, I; Guglielmana, V; Perego, R; Ramazzotti, D; Mologni, L; Piazza, R; Gambacorti Passerini, C